Can you take Clofarabine with Quadramet?
1 drug interaction and 7 additional warnings found for the following 2 drugs:
- clofarabine
- Quadramet (samarium sm 153 lexidronam)
Drug interactions
Major drug interactions
Major:
samarium sm 153 lexidronam clofarabine
Applies to: Quadramet (samarium sm 153 lexidronam) and clofarabine
Using samarium sm 153 lexidronam together with clofarabine may increase the risk of side effects that affect your bone marrow function, resulting in low numbers of different types of blood cells. You may be more likely to develop anemia, bleeding problems, or infections due to low blood cell counts. You should seek medical attention if you develop paleness, fatigue, dizziness, fainting, unusual bruising or bleeding, fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. Talk to your doctor if you have any questions or concerns. Your doctor may already be aware of the risks, but has determined that this is the best course of treatment for you and has taken appropriate precautions and is monitoring you closely for any potential complications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Food/lifestyle interactions
No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Disease interactions
7 potential interactions Applies to: 7 conditions, including Liver Disease, Infection, Sepsis, Noninfectious Colitis, and Renal Dysfunction.
Bone Marrow Depression/Low Blood Counts
Moderate:
clofarabine
Clofarabine has a moderate potential interaction with Bone Marrow Depression/Low Blood Counts.
Clofarabine causes myelosuppression which may be severe and prolonged. Serious and fatal hemorrhage, including cerebral, gastrointestinal and pulmonary hemorrhage associated with thrombocytopenia has occurred. It is recommended to monitor complete blood counts including platelets and coagulation parameters and treat accordingly. Care should be exercised when using this agent in patients with bone marrow depression.
Infection
Major:
clofarabine
Clofarabine has a major potential interaction with Infection.
Clofarabine injection may cause acute renal failure. Patients with infection, sepsis, or tumor lysis syndrome may be at increased risk of renal toxicity when treated with clofarabine injection. It is recommended to monitor patients for renal toxicity and interrupt or discontinue clofarabine injection as necessary.
Liver Disease
Moderate:
clofarabine
Clofarabine has a moderate potential interaction with Liver Disease.
Severe and fatal hepatotoxicity, including hepatitis and hepatic failure, has occurred with the use of clofarabine. Monitor hepatic function and for signs and symptoms of hepatitis and hepatic failure. It is recommended to discontinue clofarabine immediately for Grade 3 or greater liver enzyme and/or bilirubin elevation of the liver, or veno-occlusive disease is suspected. Care should be exercised when using this agent in patients with liver disease.
Noninfectious Colitis
Moderate:
clofarabine
Clofarabine has a moderate potential interaction with Noninfectious Colitis.
Fatal and serious cases of enterocolitis, including neutropenic colitis, cecitis, and C. difficile colitis, have occurred during treatment with clofarabine. This has occurred more frequently within 30 days of treatment, and in the setting of combination chemotherapy. Enterocolitis may lead to necrosis, perforation, hemorrhage or sepsis complications. Monitor patients for signs and symptoms of enterocolitis and treat promptly. Care should be exercised when treating patients presenting with symptoms of enterocolitis.
Renal Dysfunction
Moderate:
clofarabine
Clofarabine has a moderate potential interaction with Renal Dysfunction.
The use of clofarabine may cause acute renal failure. It is recommended to reduce the dose by 50% in patients with CrCl of 30 to 60 mL/min. At this time the manufacturer is not able to make a dosage recommendation in patients with CrCl less than 30 mL/min or in those on dialysis as there is insufficient information in this patient population. Care should be exercised when using this agent in patients with renal dysfunction.
Sepsis
Major:
clofarabine
Clofarabine has a major potential interaction with Sepsis.
Clofarabine injection may cause acute renal failure. Patients with infection, sepsis, or tumor lysis syndrome may be at increased risk of renal toxicity when treated with clofarabine injection. It is recommended to monitor patients for renal toxicity and interrupt or discontinue clofarabine injection as necessary.
Tumor Lysis Syndrome
Major:
clofarabine
Clofarabine has a major potential interaction with Tumor Lysis Syndrome.
Clofarabine injection may cause acute renal failure. Patients with infection, sepsis, or tumor lysis syndrome may be at increased risk of renal toxicity when treated with clofarabine injection. It is recommended to monitor patients for renal toxicity and interrupt or discontinue clofarabine injection as necessary.
Report options
More resources
clofarabine
A total of 649 drugs are known to interact with clofarabine.
- Clofarabine is in the drug class antimetabolites.
- Clofarabine is used to treat Acute Lymphoblastic Leukemia.
Quadramet
A total of 223 drugs are known to interact with Quadramet.
- Quadramet is in the drug class therapeutic radiopharmaceuticals.
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.